<DOC>
	<DOCNO>NCT02247557</DOCNO>
	<brief_summary>To evaluate efficacy safety intravesical instillation Lipotoxin treatment IC/BPS</brief_summary>
	<brief_title>Intravesical Instillation Liposome Encapsulated Botulinum Toxin A ( Lipotoxin ) Treatment Interstitial Cystitis</brief_title>
	<detailed_description>Liposome proven able carry botulinum toxin protein across cell membrane effect urothelial receptor human overactive bladder . However , therapeutic duration limit 1 month . Intravesical BOTOX injection patient interstitial cystitis ( IC ) effectively decrease pain , improve bladder capacity decrease frequency . However , need cystoscopic injection limit wide application . A total 100 eligible woman non-ulcer IC enrol receive intravesical instillation Lipotoxin contain 80mg liposome 200U BOTOX ( treatment group ) , 200U BOTOX normal saline ( N/S ) ( active control group ) normal saline ( placebo control group ) single treatment . At least 90 evaluable patient include final analysis . All patient IC symptom least 6 month , proven grade 2 diffused glomerulations cystoscopic hydrodistention ( HD ) within recent 1 year without Hunner 's lesion . Patients UTI recent 12 month , urinary tract stone . Patients proven free detrusor overactivity bladder outlet obstruction . Patients receive intravesical hyaluronic acid treatment recent 6 month , intravesical Botox injection recent 12 month . Intravesical instillation Lipotoxin OPD patient hold solution 2 hour allow bladder distention . Retreatment Lipotoxin 3 month patient report ineffective . Primary end-point change O'Leary-Sant symptom score ( include ICSI ICPI ) baseline 1 month treatment . Secondary endpoint include VAS , daily frequency , nocturia FBC record 3-day voiding diary , Qmax , void volume , PVR global response assessment ( GRA ) . Four visit require baseline screening ( first treatment ) , treatment ( V1 ) , 2 week ( V2 ) , 4 week ( V3 , primary end-point ) 12 week ( V4 ) .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Adults age 20 year old 2 . Patients symptoms frequency , urgency , nocturia , and/or bladder pain . 3 . Proven glomerulations ( least grade 2 ) cystoscopic hydrodistention anesthesia recent 1 year 4 . Free active urinary tract infection 5 . Free bladder outlet obstruction enrollment 6 . Free overt neurogenic bladder dysfunction limitation ambulation 7 . Patient his/her legally acceptable representative sign write informed consent form 1 . Hunner 's lesion proven cystoscopy 2 . Patients severe cardiopulmonary disease congestive heart failure , arrhythmia , poorly control hypertension , able receive regular followup 3 . Patients bladder outlet obstruction enrollment 4 . Patients postvoid residual &gt; 250ml 5 . Patients uncontrolled confirmed diagnosis acute urinary tract infection 6 . Patients laboratory abnormality screen include : ALT &gt; 3 x upper limit normal range , AST &gt; 3 x upper limit normal range ; Patients abnormal serum creatinine level &gt; 2 x upper limit normal range 7 . Patients contraindication urethral catheterization treatment 8 . Female patient pregnant , lactating , childbearing potential without contraception . 9 . Myasthenia gravis , Eaton Lambert syndrome . 10 . Patients serious disease consider investigator condition enter trial 11 . Patient receive intravesical treatment IC within recent 1 month 12 . Patients participate investigational drug trial within 1 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IC/PBS</keyword>
	<keyword>VAS</keyword>
	<keyword>Botulinum Toxin A</keyword>
	<keyword>Lipotoxin</keyword>
</DOC>